Home › Companies › Regeneron Pharmaceuticals, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Regeneron Pharmaceuticals, Inc.’s Form 8-K, filed June 17, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 12, 2026: 7 items on Regeneron Pharmaceuticals, Inc.’s Form 8-K, filed June 17, 2026: 5 elected · 2 approved.
Significant dissent: 3 directors (29.9%, 23.2%, 20.7% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore Regeneron Pharmaceuticals, Inc. in the interactive database Compare manager voting policies
These tallies are Regeneron Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 17, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Joseph L. Goldstein, M.D. | 72,398,297 | 30,904,254 | 170,603 | -- | 5,543,411 | 70% | Elected | — |
| Elect Director: Christine A. Poon | 79,409,070 | 24,004,880 | 59,204 | -- | 5,543,411 | 77% | Elected | — |
| Elect Director: David P. Schenkein, M.D. | 99,241,219 | 4,180,107 | 51,828 | -- | 5,543,411 | 96% | Elected | — |
| Elect Director: Craig B. Thompson, M.D. | 81,933,651 | 21,378,567 | 160,936 | -- | 5,543,411 | 79% | Elected | — |
| Elect Director: Huda Y. Zoghbi, M.D. | 100,665,234 | 2,698,397 | 109,523 | -- | 5,543,411 | 97% | Elected | — |
| 2. Ratification of Appointment of Independent Registered Public Accounting Firm The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 | 102,503,788 | 6,443,958 | 68,819 | -- | -- | 94% | Approved | — |
| 3. Advisory Vote on Executive Compensation The resolution to approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement on Schedule 14A filed April 24, 2026 | 96,469,374 | 6,898,268 | 105,512 | -- | 5,543,411 | 93% | Approved | — |
Source: Regeneron Pharmaceuticals, Inc., Form 8-K, filed with the SEC on June 17, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
1,055 asset managers disclosed a vote on at least one Regeneron Pharmaceuticals, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 7 wordings of this item as funds reported it.
70% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Joseph L. Goldstein, M.D.
Regeneron Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Joseph L. Goldstein, M.D.”): 72,398,297 for, 30,904,254 against, per its Form 8-K filed June 17, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The following nominees for Class II directors were elected to serve until the 2027 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon the following votes:”
Support: 70% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 182 asset managers below reported 31,058,888 for, 8,815,478 against, 11,211 abstained, 120 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,063,929 | 24,302 | 1 | 0 | For |
| Invesco | 3,728,116 | 0 | 0 | 0 | For |
| Dodge & Cox | 3,411,656 | 0 | 0 | 0 | For |
| BlackRock | 3,285,929 | 3,570 | 0 | 0 | For |
| Fidelity | 1,000,108 | 2,267,071 | 0 | 0 | Mixed |
| JPMorgan | 2,153,087 | 0 | 0 | 0 | For |
| TIAA | 0 | 1,816,925 | 0 | 0 | Against |
| Putnam | 1,533,988 | 0 | 0 | 0 | For |
| Capital Group | 1,278,632 | 0 | 0 | 0 | For |
| State Street | 2,648 | 1,273,728 | 0 | 0 | Against |
| T. Rowe Price | 871,316 | 361 | 0 | 0 | For |
| Charles Schwab | 788,351 | 262 | 0 | 0 | For |
| Loomis Sayles | 511,945 | 0 | 0 | 0 | For |
| American Century | 0 | 361,859 | 0 | 0 | Against |
| First Trust | 0 | 361,618 | 0 | 0 | Against |
| Pacer Funds Trust | 355,797 | 0 | 0 | 0 | For |
| Dimensional | 0 | 268,093 | 0 | 0 | Against |
| Jackson National | 105,912 | 147,059 | 0 | 0 | Mixed |
| Prudential/PGIM | 176,021 | 1,777 | 0 | 0 | For |
| Federated Hermes | 177,248 | 0 | 0 | 0 | For |
| WisdomTree | 0 | 159,523 | 0 | 0 | Against |
| MASTER INVESTMENT PORTFOLIO | 156,099 | 0 | 0 | 0 | For |
| ProShares | 0 | 151,342 | 0 | 0 | Against |
| Equitable | 101,000 | 46,894 | 0 | 0 | Mixed |
| Victory Capital | 36,660 | 109,787 | 0 | 0 | Mixed |
Showing the 25 largest of 182 asset managers. All 182 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
77% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Christine A. Poon
Regeneron Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Christine A. Poon”): 79,409,070 for, 24,004,880 against, per its Form 8-K filed June 17, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The following nominees for Class II directors were elected to serve until the 2027 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon the following votes:”
Support: 77% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 182 asset managers below reported 34,101,720 for, 5,772,500 against, 11,210 abstained, 120 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,087,753 | 331 | 0 | 0 | For |
| Invesco | 3,728,116 | 0 | 0 | 0 | For |
| Dodge & Cox | 3,411,656 | 0 | 0 | 0 | For |
| BlackRock | 3,287,026 | 2,473 | 0 | 0 | For |
| Fidelity | 3,236,665 | 30,514 | 0 | 0 | For |
| JPMorgan | 2,153,087 | 0 | 0 | 0 | For |
| TIAA | 0 | 1,816,925 | 0 | 0 | Against |
| Putnam | 1,533,988 | 0 | 0 | 0 | For |
| Capital Group | 1,278,632 | 0 | 0 | 0 | For |
| State Street | 2,648 | 1,273,728 | 0 | 0 | Against |
| T. Rowe Price | 871,316 | 361 | 0 | 0 | For |
| Charles Schwab | 788,613 | 0 | 0 | 0 | For |
| Loomis Sayles | 511,945 | 0 | 0 | 0 | For |
| American Century | 0 | 361,859 | 0 | 0 | Against |
| First Trust | 0 | 361,618 | 0 | 0 | Against |
| Pacer Funds Trust | 355,797 | 0 | 0 | 0 | For |
| Dimensional | 0 | 268,093 | 0 | 0 | Against |
| Jackson National | 249,121 | 3,850 | 0 | 0 | For |
| Prudential/PGIM | 176,021 | 1,777 | 0 | 0 | For |
| Federated Hermes | 177,248 | 0 | 0 | 0 | For |
| WisdomTree | 159,523 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 156,099 | 0 | 0 | 0 | For |
| ProShares | 0 | 151,342 | 0 | 0 | Against |
| Equitable | 147,894 | 0 | 0 | 0 | For |
| Victory Capital | 36,660 | 109,787 | 0 | 0 | Mixed |
Showing the 25 largest of 182 asset managers. All 182 are in the interactive database (link above).
Combines 7 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: David P. Schenkein, M.D.
Regeneron Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: David P. Schenkein, M.D.”): 99,241,219 for, 4,180,107 against, per its Form 8-K filed June 17, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The following nominees for Class II directors were elected to serve until the 2027 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon the following votes:”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 182 asset managers below reported 39,607,708 for, 265,616 against, 12,106 abstained, 120 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,088,034 | 50 | 0 | 0 | For |
| Invesco | 3,728,116 | 0 | 0 | 0 | For |
| Dodge & Cox | 3,411,656 | 0 | 0 | 0 | For |
| BlackRock | 3,289,499 | 0 | 0 | 0 | For |
| Fidelity | 3,267,179 | 0 | 0 | 0 | For |
| JPMorgan | 2,153,087 | 0 | 0 | 0 | For |
| TIAA | 1,816,925 | 0 | 0 | 0 | For |
| Putnam | 1,533,988 | 0 | 0 | 0 | For |
| Capital Group | 1,278,632 | 0 | 0 | 0 | For |
| State Street | 1,276,376 | 0 | 0 | 0 | For |
| T. Rowe Price | 871,677 | 0 | 0 | 0 | For |
| Charles Schwab | 788,613 | 0 | 0 | 0 | For |
| Loomis Sayles | 511,945 | 0 | 0 | 0 | For |
| American Century | 361,859 | 0 | 0 | 0 | For |
| First Trust | 361,618 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 355,797 | 0 | 0 | 0 | For |
| Dimensional | 268,093 | 0 | 0 | 0 | For |
| Jackson National | 252,971 | 0 | 0 | 0 | For |
| Prudential/PGIM | 177,798 | 0 | 0 | 0 | For |
| Federated Hermes | 177,248 | 0 | 0 | 0 | For |
| WisdomTree | 159,523 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 156,099 | 0 | 0 | 0 | For |
| ProShares | 151,342 | 0 | 0 | 0 | For |
| Equitable | 101,000 | 46,894 | 0 | 0 | Mixed |
| Victory Capital | 146,447 | 0 | 0 | 0 | For |
Showing the 25 largest of 182 asset managers. All 182 are in the interactive database (link above).
Combines 7 wordings of this item as funds reported it.
79% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Craig B. Thompson, M.D.
Regeneron Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Craig B. Thompson, M.D.”): 81,933,651 for, 21,378,567 against, per its Form 8-K filed June 17, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The following nominees for Class II directors were elected to serve until the 2027 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon the following votes:”
Support: 79% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 182 asset managers below reported 34,150,890 for, 5,723,328 against, 11,211 abstained, 120 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,087,783 | 299 | 1 | 0 | For |
| Invesco | 3,728,116 | 0 | 0 | 0 | For |
| Dodge & Cox | 3,411,656 | 0 | 0 | 0 | For |
| BlackRock | 3,287,026 | 2,473 | 0 | 0 | For |
| Fidelity | 3,236,665 | 30,514 | 0 | 0 | For |
| JPMorgan | 2,153,087 | 0 | 0 | 0 | For |
| TIAA | 0 | 1,816,925 | 0 | 0 | Against |
| Putnam | 1,533,988 | 0 | 0 | 0 | For |
| Capital Group | 1,278,632 | 0 | 0 | 0 | For |
| State Street | 2,648 | 1,273,728 | 0 | 0 | Against |
| T. Rowe Price | 871,316 | 361 | 0 | 0 | For |
| Charles Schwab | 788,613 | 0 | 0 | 0 | For |
| Loomis Sayles | 511,945 | 0 | 0 | 0 | For |
| American Century | 0 | 361,859 | 0 | 0 | Against |
| First Trust | 0 | 361,618 | 0 | 0 | Against |
| Pacer Funds Trust | 355,797 | 0 | 0 | 0 | For |
| Dimensional | 0 | 268,093 | 0 | 0 | Against |
| Jackson National | 249,121 | 3,850 | 0 | 0 | For |
| Prudential/PGIM | 176,021 | 1,777 | 0 | 0 | For |
| Federated Hermes | 177,248 | 0 | 0 | 0 | For |
| WisdomTree | 159,523 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 156,099 | 0 | 0 | 0 | For |
| ProShares | 0 | 151,342 | 0 | 0 | Against |
| Equitable | 101,000 | 46,894 | 0 | 0 | Mixed |
| Victory Capital | 36,660 | 109,787 | 0 | 0 | Mixed |
Showing the 25 largest of 182 asset managers. All 182 are in the interactive database (link above).
Combines 7 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Huda Y. Zoghbi, M.D.
Regeneron Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Huda Y. Zoghbi, M.D.”): 100,665,234 for, 2,698,397 against, per its Form 8-K filed June 17, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The following nominees for Class II directors were elected to serve until the 2027 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon the following votes:”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 182 asset managers below reported 39,584,487 for, 289,732 against, 11,211 abstained, 120 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,088,046 | 37 | 1 | 0 | For |
| Invesco | 3,728,116 | 0 | 0 | 0 | For |
| Dodge & Cox | 3,411,656 | 0 | 0 | 0 | For |
| BlackRock | 3,289,499 | 0 | 0 | 0 | For |
| Fidelity | 3,267,179 | 0 | 0 | 0 | For |
| JPMorgan | 2,153,087 | 0 | 0 | 0 | For |
| TIAA | 1,816,925 | 0 | 0 | 0 | For |
| Putnam | 1,533,988 | 0 | 0 | 0 | For |
| Capital Group | 1,278,632 | 0 | 0 | 0 | For |
| State Street | 1,276,376 | 0 | 0 | 0 | For |
| T. Rowe Price | 871,677 | 0 | 0 | 0 | For |
| Charles Schwab | 788,613 | 0 | 0 | 0 | For |
| Loomis Sayles | 511,945 | 0 | 0 | 0 | For |
| American Century | 361,859 | 0 | 0 | 0 | For |
| First Trust | 361,618 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 355,797 | 0 | 0 | 0 | For |
| Dimensional | 268,093 | 0 | 0 | 0 | For |
| Jackson National | 252,971 | 0 | 0 | 0 | For |
| Prudential/PGIM | 177,798 | 0 | 0 | 0 | For |
| Federated Hermes | 177,248 | 0 | 0 | 0 | For |
| WisdomTree | 159,523 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 156,099 | 0 | 0 | 0 | For |
| ProShares | 151,342 | 0 | 0 | 0 | For |
| Equitable | 101,000 | 46,894 | 0 | 0 | Mixed |
| Victory Capital | 146,447 | 0 | 0 | 0 | For |
Showing the 25 largest of 182 asset managers. All 182 are in the interactive database (link above).
Combines 26 wordings of this item as funds reported it.
93% Approved · of votes cast
Prior year: 93.3% for (June 13, 2025 meeting) unchanged
Description as filed by funds: Proposal to approve, on an advisory basis, compensation of the Named Executive Officers.
Regeneron Pharmaceuticals, Inc.’s own tally for this item (“3. Advisory Vote on Executive Compensation The resolution to approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement on Schedule ”): 96,469,374 for, 6,898,268 against — passed, per its Form 8-K filed June 17, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3 – Advisory Vote on Executive Compensation The resolution to approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement on Schedule 14A filed April 24, 2026 was approved based upon the following votes:”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,087,995 | 87 | 1 | 0 | For |
| Invesco | 3,728,116 | 0 | 0 | 0 | For |
| Dodge & Cox | 3,411,656 | 0 | 0 | 0 | For |
| BlackRock | 3,289,499 | 0 | 0 | 0 | For |
| Fidelity | 3,267,179 | 0 | 0 | 0 | For |
| JPMorgan | 2,153,087 | 0 | 0 | 0 | For |
| TIAA | 1,816,925 | 0 | 0 | 0 | For |
| Putnam | 1,533,988 | 0 | 0 | 0 | For |
| Capital Group | 0 | 1,278,632 | 0 | 0 | Against |
| State Street | 1,276,358 | 18 | 0 | 0 | For |
| T. Rowe Price | 871,677 | 0 | 0 | 0 | For |
| Charles Schwab | 788,613 | 0 | 0 | 0 | For |
| Loomis Sayles | 511,945 | 0 | 0 | 0 | For |
| American Century | 333,081 | 28,778 | 0 | 0 | Mixed |
| First Trust | 361,618 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 355,797 | 0 | 0 | 0 | For |
| Dimensional | 268,093 | 0 | 0 | 0 | For |
| Jackson National | 252,971 | 0 | 0 | 0 | For |
| Prudential/PGIM | 177,798 | 0 | 0 | 0 | For |
| Federated Hermes | 177,248 | 0 | 0 | 0 | For |
| WisdomTree | 159,523 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 156,099 | 0 | 0 | 0 | For |
| ProShares | 151,342 | 0 | 0 | 0 | For |
| Equitable | 147,894 | 0 | 0 | 0 | For |
| Victory Capital | 146,447 | 0 | 0 | 0 | For |
Fund voting reports, all 178 managers: 38,405,161 for, 1,468,309 against, 11,211 abstained, 120 not voted. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 4,441,074 | 6 | 0 | 0 | For |
| Dodge & Cox | 4,216,225 | 0 | 0 | 0 | For |
| Invesco | 4,214,312 | 0 | 0 | 0 | For |
| State Street | 3,020,753 | 33,716 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,612,941 | 0 | 0 | 0 | For |
| Putnam | 2,368,534 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,221,613 | 0 | 0 | 0 | For |
| Wellington | 2,008,083 | 0 | 0 | 0 | For |
| Nuveen | 2,000,851 | 706 | 0 | 0 | For |
| Loomis Sayles | 1,603,668 | 62,432 | 0 | 0 | For |
| Capital Group | 4,045 | 1,445,673 | 0 | 0 | Against |
| Fidelity | 1,405,133 | 0 | 0 | 0 | For |
| Vanguard | 1,036,459 | 0 | 0 | 0 | For |
| Amundi | 0 | 985,490 | 0 | 0 | Against |
| Charles Schwab | 839,240 | 0 | 0 | 0 | For |
| Northern Trust | 792,044 | 7,810 | 0 | 0 | For |
| AQR | 726,916 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 538,915 | 0 | 0 | 0 | For |
| Neuberger Berman | 510,993 | 0 | 0 | 0 | For |
| Goldman Sachs | 483,115 | 0 | 0 | 0 | For |
| Legal & General Investment Management Ltd | 458,093 | 2,374 | 0 | 0 | For |
| American Century | 428,477 | 29,447 | 0 | 0 | Mixed |
| Two Sigma | 445,565 | 0 | 0 | 0 | For |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 406,794 | 0 | 0 | 0 | For |
| UBS | 0 | 370,679 | 0 | 0 | Against |
Institutional-manager reports, all 917 managers: 50,322,623 for, 5,453,229 against, 7,337 abstained, 21,654 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 7 wordings of this item as funds reported it.
94% Approved · of votes cast
Prior year: 94.5% for (June 13, 2025 meeting) ▼ 0.5 pts
Description as filed by funds: Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.
Regeneron Pharmaceuticals, Inc.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Public Accounting Firm The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the ”): 102,503,788 for, 6,443,958 against — passed, per its Form 8-K filed June 17, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Ratification of Appointment of Independent Registered Public Accounting Firm The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was approved based upon the foll…”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 185 asset managers below reported 39,819,363 for, 100,585 against, 11,210 abstained, 120 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,078,691 | 9,540 | 0 | 0 | For |
| Invesco | 3,728,116 | 0 | 0 | 0 | For |
| Dodge & Cox | 3,411,656 | 0 | 0 | 0 | For |
| BlackRock | 3,288,926 | 573 | 0 | 0 | For |
| Fidelity | 3,267,179 | 0 | 0 | 0 | For |
| JPMorgan | 2,153,087 | 0 | 0 | 0 | For |
| TIAA | 1,816,925 | 0 | 0 | 0 | For |
| Putnam | 1,533,988 | 0 | 0 | 0 | For |
| Capital Group | 1,278,632 | 0 | 0 | 0 | For |
| State Street | 1,276,358 | 18 | 0 | 0 | For |
| T. Rowe Price | 871,677 | 0 | 0 | 0 | For |
| Charles Schwab | 788,613 | 0 | 0 | 0 | For |
| Loomis Sayles | 511,945 | 0 | 0 | 0 | For |
| American Century | 361,859 | 0 | 0 | 0 | For |
| First Trust | 361,618 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 355,797 | 0 | 0 | 0 | For |
| Dimensional | 268,093 | 0 | 0 | 0 | For |
| Jackson National | 252,971 | 0 | 0 | 0 | For |
| Prudential/PGIM | 177,798 | 0 | 0 | 0 | For |
| Federated Hermes | 177,248 | 0 | 0 | 0 | For |
| WisdomTree | 159,523 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 156,099 | 0 | 0 | 0 | For |
| ProShares | 151,342 | 0 | 0 | 0 | For |
| Equitable | 147,894 | 0 | 0 | 0 | For |
| Victory Capital | 146,447 | 0 | 0 | 0 | For |
Showing the 25 largest of 185 asset managers. All 185 are in the interactive database (link above).
Not shown here: this season’s fund filings also report 1 item from the meeting of June 13, 2025, which belongs to the 2024-2025 season. A meeting outside this season’s July 1 to June 30 window is not counted in this page’s items or in its totals of asset managers and fund votes.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 104,000,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 9.70% |
| 2 | Invesco | 3.58% |
| 3 | Dodge & Cox | 3.28% |
| 4 | BlackRock | 3.16% |
| 5 | Fidelity | 3.14% |
| 6 | JPMorgan | 2.07% |
| 7 | TIAA | 1.75% |
| 8 | Putnam | 1.47% |
| 9 | Capital Group | 1.23% |
| 10 | State Street | 1.23% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 4.27% |
| 2 | Dodge & Cox | 4.05% |
| 3 | Invesco | 4.05% |
| 4 | State Street | 2.94% |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 2.51% |
| 6 | Putnam | 2.28% |
| 7 | T. Rowe Price | 2.14% |
| 8 | Wellington | 1.93% |
| 9 | Nuveen | 1.92% |
| 10 | Loomis Sayles | 1.60% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| BlackRock | 8,947,735 | 8.60% | Form 13F, quarter ended March 31, 2026 |
| State Street | 4,664,478 | 4.49% | Form 13F, quarter ended March 31, 2026 |
| JPMorgan Chase | 4,311,806 | 4.15% | Form 13F, quarter ended March 31, 2026 |
| Franklin Templeton | 2,722,071 | 2.62% | Form 13F, quarter ended March 31, 2026 |
| T. Rowe Price | 2,177,527 | 2.09% | Form 13F, quarter ended March 31, 2026 |
| Wellington Management | 1,837,459 | 1.77% | Form 13F, quarter ended March 31, 2026 |
| Invesco | 1,724,478 | 1.66% | Form 13F, quarter ended March 31, 2026 |
| FMR (Fidelity) | 1,518,192 | 1.46% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 104,000,000 shares outstanding, as reported by Regeneron Pharmaceuticals, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Regeneron Pharmaceuticals, Inc.'s shareholder meeting held June 12, 2026, in the 2025-2026 proxy season, 1,055 asset managers reported votes on at least one of its 7 ballot items in their SEC Form N-PX filings, covering 9,087 separate fund positions. On the most widely held item on that ballot — Proposal to approve, on an advisory basis, compensation of the Named Executive Officers. — Regeneron Pharmaceuticals, Inc.'s filing reports the proposal as approved, with 93% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Regeneron Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 17, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Regeneron Pharmaceuticals, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Regeneron Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Regeneron Pharmaceuticals (REGN) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/regeneron-pharmaceuticals-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.